SOURCE: OctoPlus

March 23, 2007 04:10 ET

OctoPlus to present at BioCapital Europe conference

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- March 23, 2007 --

OctoPlus N.V. (Euronext: OCTO), the drug delivery and development company, announces today that its CFO will present at the BioCapital Europe conference in Amsterdam next week.

Hans Pauli, Chief Financial Officer, will present on Wednesday, 28 March at 2:35 PM EST.

For further information, please contact:

Rianne Roukema, Corporate Communications: +31 (71) 524 4044
About OctoPlus

OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on its proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics and other drugs.

OctoPlus is also a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that OctoPlus derives from rendering formulation and manufacturing services help to support its own drug development programs.

OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information